Crescita Therapeutics (CTX) Q1 2025 earnings summary

Executive summary

• Q1-25 revenue was $3.54M, down 29% year-over-year, mainly due to lower manufacturing sales and a decline in e-commerce and export revenue in skincare, partially offset by incremental revenue from the Aquafolia brand acquired in June 2024 and timing of order fulfillment in Manufacturing.

• Net loss increased to $932K from $626K in Q1-24, reflecting lower gross profit and higher loss from operations, partially offset by reduced SG&A and R&D expenses.

• Adjusted EBITDA loss widened to $679K from $325K year-over-year.

• Cash and cash equivalents at quarter-end were $8.54M, with working capital of $8.97M.

• Management expects topline improvement in coming quarters as larger orders are delivered.

Financial highlights

• Gross profit was $1.75M (49.4% margin), down from $2.41M (48.3%) in Q1-24.

• Operating expenses decreased to $2.81M from $3.14M, mainly due to lower headcount and commercial partnership fees.

• Cash used in operating activities was $513K, compared to $378K provided in Q1-24.

• Loss per share was $(0.05), compared to $(0.03) in Q1-24.

• Cash and cash equivalents at quarter-end were $8.54M, down $735K from prior year.

Outlook and guidance

• Management believes current cash, working capital, and undrawn credit facility ($2.08M available) are sufficient to fund operations and growth initiatives.

• The ability to reach sustained profitability depends on successful execution of the growth strategy and may require additional financing if revenue targets are not met.

• Management anticipates revenue growth in subsequent quarters as delayed orders are fulfilled.

• Focus remains on disciplined capital deployment and balancing growth investments with financial strength.